RESUMEN
In a study of 57 rabbits, we found that zinc played a vital role in the growth of the rabbit and in its immunocompetence. Both humoral and cellular immunity were depressed in the zinc-deficient rabbit. Not only did zinc-deficient animals fail to gain weight, differing in that respect from rabbits on a regular diet, but they also had a high death rate, in contrast with no deaths among normal rabbits. Herpes simplex virus keratitis, both epithelial and stromal, was more severe in the zinc-deficient rabbit but was not improved by local zinc replacement (zinc sulphate ointment, 0.05%); Zinc sulphate ointment (1%), which is four times stronger than commercially available zinc ophthalmic preparations, was severely toxic for the rabbit cornea.
Asunto(s)
Queratitis Dendrítica/complicaciones , Zinc/deficiencia , Administración Tópica , Animales , Formación de Anticuerpos , Dieta , Femenino , Queratitis Dendrítica/diagnóstico , Queratitis Dendrítica/tratamiento farmacológico , Masculino , Conejos , Pruebas Cutáneas , Sulfatos/administración & dosificación , Sulfatos/toxicidad , Zinc/administración & dosificación , Zinc/toxicidad , Sulfato de ZincRESUMEN
PURPOSE: We studied the efficacy of topically applied lodoxamide tromethamine 0.1% in the treatment of superior limbic keratoconjunctivitis. METHODS: Three patients with clinical findings of bilateral superior limbic keratoconjunctivitis. were treated with topical lodoxamide tromethamine four times daily in both eyes. RESULTS: While the patients were taking lodoxamide tromethamine, symptoms and objective findings resolved. CONCLUSIONS: Topically applied lodoxamide tromethamine 0.1% is useful in the treatment of superior limbic keratoconjunctivitis. There may be a role for mast cell stabilizers in the treatment of this disorder.
Asunto(s)
Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Queratoconjuntivitis/tratamiento farmacológico , Ácido Oxámico/análogos & derivados , Trometamina/análogos & derivados , Administración Tópica , Adulto , Conjuntiva/efectos de los fármacos , Femenino , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Nitrilos , Soluciones Oftálmicas , Ácido Oxámico/administración & dosificación , Ácido Oxámico/uso terapéutico , Trometamina/administración & dosificación , Trometamina/uso terapéuticoRESUMEN
PURPOSE: Two multicenter studies compared the efficacy and safety of rimexolone 1% ophthalmic suspension (Vexol 1%, Alcon) and 1% prednisolone acetate (Pred Forte, Allergan). METHODS: Patients with acute uveitis, recurrent iridocyclitis, or chronic uveitis treatable by topical corticosteroid were enrolled. Treatment regimen was one or two drops every hour during Week 1, every two hours during Week 2, four times a day during Week 3, and once a day for the last three days. Efficacy and safety were determined on Days 3, 4, 7 to 10, 14, 21, and 28. A poststudy evaluation was conducted 36 to 72 hours after treatment was stopped. RESULTS: When anterior chamber cell and flare were measured, rimexolone 1% was found to be as effective as 1% prednisolone. The largest difference observed between treatments was 0.5 score unit, not clinically significant. There were no statistically significant differences in cell scores in either study (P > .05). No statistically significant differences in flare scores were found except at Day 28 in Study One (P = .04). Also, prednisolone was found to be more likely than rimexolone to cause a clinically significant increase (10 mm Hg or more) in intraocular pressure (1.7 times more likely in Study One, eight times more likely in Study Two). CONCLUSION: Rimexolone 1% ophthalmic suspension is safe and effective for the treatment of uveitis.